Equities

Laboratorio Farmaceutico Erfo SpA

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Laboratorio Farmaceutico Erfo SpA

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (EUR)1.35
  • Today's Change0.01 / 0.75%
  • Shares traded9.00k
  • 1 Year change+3.45%
  • Beta1.0130
Data delayed at least 15 minutes, as of Feb 10 2026 12:21 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Laboratorio Farmaceutico Erfo SpA is an Italy-based pharmaceutical company primarily engaged in the nutraceutical sector. The Company specializes in the production of nutritional supplements, that thanks to research and development carried out internally and in collaboration with the University Campus Bio-Medico of Rome and the University of Messina provides products with a scientific value in different therapeutic areas. The Company operates globally.

  • Revenue in EUR (TTM)7.68m
  • Net income in EUR387.72k
  • Incorporated2010
  • Employees47.00
  • Location
    Laboratorio Farmaceutico Erfo SpAViale Geki RussoZona Artigianale Loc. PontegalloVILLAFRANCA TIRRENA 98049ItalyITA
  • Websitehttps://www.erfo.it/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Krebs Biochemicals And Industries Ltd2.52m-2.54m11.28m202.00------4.48-12.74-12.7412.63-73.150.15410.321120.111,347,327.00-15.56-16.90-39.83-26.5692.0420.39-100.95-55.630.0394-3.283.55---14.105.33-36.55---17.65--
Simply Solventless Concentrates Ltd19.01m2.58m11.34m192.009.070.57863.140.59630.01760.01760.26430.27650.7251.117.89159,949.409.84--13.15--28.99--13.57--0.7405-0.59810.3241--120.93---599.34------
Cellectar Biosciences Inc0.00-15.82m11.42m11.00--1.37-----10.78-10.780.002.940.00----0.00-72.62-104.57-141.24-133.43------------0.00-------4.23--33.54--
BIOGENED SA27.36m1.36m11.91m223.008.741.145.480.43532.332.3346.8717.841.331.745.43--5.634.167.436.0265.2568.274.243.961.403.830.3443--16.0918.9314.2235.568.39--
Millennium Pharmacon Internationl Tbk PT199.58m839.23k11.97m1.18k14.260.79745.950.0613.1913.193,135.74235.762.176.554.683,382,665,000.000.91181.264.425.888.498.440.42080.53890.73631.360.738511.7316.457.51-48.8416.535.5314.87
Laboratorio Farmaceutico Erfo SpA7.68m387.72k12.06m47.0029.521.448.991.570.04540.04540.89640.92990.67343.867.09187,405.604.699.365.9911.5038.2747.806.9715.921.2119.410.1559--1.596.03-33.74-22.47----
Sotac Pharmaceuticals Ltd7.53m804.94k12.09m67.0015.032.358.631.617.877.8773.6150.390.68182.862.6712,149,600.008.465.8116.2812.4737.2625.5912.404.690.97372.300.3854---6.5927.66124.25146.8911.66--
Nutrition Profess PCL29.19m1.78m12.10m--6.780.91694.070.41470.55120.55129.024.08----------------85.40--6.11--3.7114.400.1617---1.84---15.21------
Phapros Tbk PT42.77m-10.47m12.51m1.26k--0.6423--0.2924-249.48-249.481,019.16463.990.5472.361.88649,537,700.00-13.71-2.15-21.02-4.1141.2648.61-25.06-3.951.02-2.190.6425---25.80-7.60-3,721.67---13.99--
Data as of Feb 10 2026. Currency figures normalised to Laboratorio Farmaceutico Erfo SpA's reporting currency: Euro EUR
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.